Health&Life Co

Health&Life Co Receivables

The Accounts Receivable of Health&Life Co (1781.TWO) as of Oct 27, 2026 is 139.00 M TWD. In the previous year, Accounts Receivable was 103.87 M TWD — a change of 33.82% (higher).

Receivables

139.00 MTWD

YoY

33.82%

Last updated:

Accounts Receivable of Health&Life Co is 2024 139.00 M TWD. Accounts Receivable of Health&Life Co was 2023 103.87 M TWD. It decreases by 33.82% higher compared to the previous year.

The Health&Life Co Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2017
56.70 M TWD
Jan 1, 2018
65.91 M TWD
Jan 1, 2019
55.34 M TWD
Jan 1, 2020
87.82 M TWD
Jan 1, 2021
102.12 M TWD
Jan 1, 2022
140.61 M TWD
Jan 1, 2023
103.87 M TWD
Jan 1, 2024
139.00 M TWD
The Health&Life Co Receivables history
YEARReceivablesYoY
139.00 MTWD+33.82%
103.87 MTWD-26.12%
140.61 MTWD+37.69%
102.12 MTWD+16.27%
87.82 MTWD+58.69%
55.34 MTWD-16.03%
65.91 MTWD+16.24%
56.70 MTWD-33.31%
85.02 MTWD+153.07%
33.60 MTWD-73.42%
126.39 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Health&Life Co Stock analysis

What does Health&Life Co do? Health&Life Co Ltd generates revenue through the manufacturing and distribution of cardiovascular disease, in-vitro diagnostics, and respiratory care products. The company's primary products include electronic sphygmomanometers such as blood pressure monitors, nebulizers, and blood glucose monitoring systems, which measure and record systolic and diastolic blood pressure and glucose levels. These products are sold domestically in Taiwan and internationally to overseas markets. The firm targets healthcare providers, clinics, and consumers seeking home health monitoring solutions for chronic conditions like hypertension and diabetes. The company's product portfolio focuses on electronic sphygmomanometers, which are essential for daily health monitoring. By offering devices that measure blood pressure and glucose levels, Health&Life Co Ltd caters to patients managing cardiovascular and metabolic diseases. The domestic market in Taiwan serves as a key sales channel, while overseas markets provide additional growth opportunities for the firm's diagnostic and respiratory care products. Health&Life Co Ltd's business model relies on direct sales of medical devices to healthcare institutions and end-users. The firm's electronic sphygmomanometers, including blood pressure monitors and blood glucose systems, are distributed through both domestic and international channels. This approach ensures consistent revenue streams from the ongoing demand for home health monitoring equipment among patients with chronic conditions. Health&Life Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Health&Life Co stock

Accounts Receivable of Health&Life Co is 139.00 M TWD in 2024.

Accounts Receivable of Health&Life Co changed from 103.87 M TWD to 139.00 M TWD, representing a 33.82% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Health&Life Co since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Health&Life Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Health&Life Co

All Key Metrics — Health&Life Co